ArticleJournal of surgical oncology2023
Tumor deposits are associated with a higher risk of peritoneal disease in non-metastatic colorectal cancer patients.
Article in Journal of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05923450 (Presence of Tumor Deposits is a Strong Indicator of Poor Outcome in Stage III Colorectal Cancers Undergoing Radical Surgery), which is not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Presence of Tumor Deposits is a Strong Indicator of Poor Outcome in Stage III Colorectal Cancers Undergoing Radical Surgery: Need for an Urgent Revision of the Staging System
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Association between the histopathologic measurement of tumor-visceral peritoneal distance and prognosis in T3 colon adenocarcinoma.Pathology oncology research : POR · 2026Article
- Prognostic impact and clinical staging adjustment of tumor deposits in postoperative radioiodine therapy for differentiated thyroid cancer.Endocrine · 2025Article
- Tumor Deposits in Non-Metastatic Colorectal Cancer as a Risk Factor of Peritoneal Metastasis.International journal of medical sciences · 2025Article
- Utilizing tumor deposit count as a stratification criterion in revising TNM staging system for patients with colorectal cancer: a nomogram review study.Frontiers in oncology · 2025Article
- Unraveling the routes to distant metastases in colorectal cancer: Tumor deposits and lymph node metastases as the gateway.Cancer communications (London, England) · 2024Article
- Prognostic Value of Tumor Deposits in Patients with Colorectal Cancer.Journal of Cancer · 2024Article
- Negative prognostic impact of tumor deposits in stage III colorectal cancer patients.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesTumor deposit (TD) is a poor prognostic factor in colorectal cancer (CRC) patients. This study aimed to determine whether TD carry the same risk of peritoneal recurrence as known high-risk (HR) features in CRC patients.
methodsA retrospective cohort-study of stage I-III CRC patients from 2010 to 2015 was conducted. TD group was defined by the presence of TD on histopathology whereas HR group was defined by the presence of obstruction, perforation, or T4-stage.
resultsA total of 151 patients with CRC were identified, of which 50 had TD and 101 had a HR feature. The overall risk of peritoneal recurrence was higher in the TD group versus HR group (36.0% vs. 19.8%, p = 0.03). The risk of peritoneum as the site of first recurrence was also higher in the TD group (22.0% vs. 12.9%, p = 0.03). Overall cancer recurrence at any site was also higher in the TD group (56.0% vs. 34.7%, p = 0.01). Median time to first recurrence was 1.2 (0.7-1.9) years in the TD group compared to 1.4 (0.8-2.1) years in the HR group (p = 0.31).
conclusionsIn non-metastatic CRC patients, TD might have a higher risk of tumor recurrence versus their HR counterparts. Alternative strategies for surveillance and treatment should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.